Literature DB >> 14591136

An analysis of the significance of performance errors on the Trail Making Test in polysubstance users.

R J McCaffrey1, M M Krahula, R G Heimberg.   

Abstract

The Trail Making Test performance of a group of polysubstance users was evaluated in order to analyze the stability of performance errors between two administrations. Two categories of errors were identified: sequential (Part A) and sequential and/or perseverative (Part B). The general findings revealed statistically significant test-retest effects. The utility of performance errors as indicators of stable CNS dysfunction is discussed in view of these findings.

Entities:  

Year:  1989        PMID： 14591136

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN： 0887-6177            Impact factor:   2.813


  4 in total

1.  Trail Making Test error analysis in classic motor neuron disease.

Authors:  Foteini Christidi; Evangelia Kararizou; Nikolaos I Triantafyllou; George P Paraskevas; Ioannis Zalonis
Journal:  Neurol Sci       Date:  2012-11-18       Impact factor: 3.307

2.  Trail Making Test errors in normal aging, mild cognitive impairment, and dementia.

Authors:  Lee Ashendorf; Angela L Jefferson; Maureen K O'Connor; Christine Chaisson; Robert C Green; Robert A Stern
Journal:  Arch Clin Neuropsychol       Date:  2008-02-21       Impact factor: 2.813

3.  Color Trails Test: A New Set of Data on Cognitive Flexibility and Processing Speed in Schizophrenia.

Authors:  Ernest Tyburski; Ewa Karabanowicz; Monika Mak; Zofia Lebiecka; Agnieszka Samochowiec; Justyna Pełka-Wysiecka; Leszek Sagan; Jerzy Samochowiec
Journal:  Front Psychiatry       Date:  2020-06-09       Impact factor: 4.157

4.  Trajectory Pattern of Cognitive Decline in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy.

Authors:  Sandrine Brice; Sonia Reyes; Aude Jabouley; Carla Machado; Christina Rogan; Nathalie Gastellier; Nassira Alili; Stephanie Guey; Eric Jouvent; Dominique Hervé; Sophie Tezenas du Montcel; Hugues Chabriat
Journal:  Neurology       Date:  2022-06-15       Impact factor: 11.800
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.